Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NeOnc Technologies Holdings, Inc. ( (NTHI) ) has provided an update.
On June 6, 2025, NeOnc Technologies Holdings, Inc. announced the appointment of Dr. Josh Neman as Chief Clinical Officer. Dr. Neman, a recognized leader in cancer neuroscience, will lead the company’s clinical development strategy and expand research collaborations. His appointment is expected to accelerate the completion of four clinical trials, including the lead asset NEO100, and strengthen NeOnc’s path toward FDA approval. This strategic move also aligns with the company’s exploration of AI and quantum computing to enhance its drug delivery platform.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a publicly traded, clinical-stage biopharmaceutical company focused on developing innovative therapies for brain and central nervous system cancers. The company’s lead programs, including NEO100 and NEO212, utilize proprietary formulations to bypass the blood-brain barrier and target malignancies with precision. NeOnc holds a robust intellectual property portfolio with 176 patents worldwide, indicating strong commercialization potential.
Average Trading Volume: 70,294
For an in-depth examination of NTHI stock, go to TipRanks’ Overview page.